Development of a universal tumor-specific CAR T cell therapy; carbohydrate-targeting CAR T cells
Aim of study
The recent introduction of T cell immunotherapy in clinical oncology represents a revolution in the management of subsets of patients suffering from malignancies previously deemed incurable. Despite highly encouraging results, the highly personalized nature of such interventions in their current form greatly limits their general applicability in patient care. In the present project we aim to develop a novel, broadly applicable "universal" immunotherapeutic regimen for the treatment of cancer. The aim will be to assess the efficacy and safety of carbohydrate-specific CAR T cell immunotherapy.
Expected injury
S.c. tumors cause minimal discomfort. T cell therapy generally causes transient and reversible weight-loss.
Benefit
Experiments will facilitate optimization of T-cell immunotherapy, allowing increased efficacy and minimization of side-effects. If successful, our treatment regimen offers a radically new treatment strategy for management of solid tumors. Experiments are designed to provide detailed knowledge of mechanism-of-action, efficacy and side-effect profile, and thus serve as an experimental basis to pave the way for future clinical evaluation.
Experiment size
The experimental setup includes a total of 3710 inbred mice, details of the various strains are further specified in the designated section of the application.
3R compliance
Group sizes are kept at a minimum required for statistically firm conclusions. Use of bioluminescence and extensive ex vivo studies yields a lot of information from each experiment and greatly limits the number of animals needed.
The recent introduction of T cell immunotherapy in clinical oncology represents a revolution in the management of subsets of patients suffering from malignancies previously deemed incurable. Despite highly encouraging results, the highly personalized nature of such interventions in their current form greatly limits their general applicability in patient care. In the present project we aim to develop a novel, broadly applicable "universal" immunotherapeutic regimen for the treatment of cancer. The aim will be to assess the efficacy and safety of carbohydrate-specific CAR T cell immunotherapy.
Expected injury
S.c. tumors cause minimal discomfort. T cell therapy generally causes transient and reversible weight-loss.
Benefit
Experiments will facilitate optimization of T-cell immunotherapy, allowing increased efficacy and minimization of side-effects. If successful, our treatment regimen offers a radically new treatment strategy for management of solid tumors. Experiments are designed to provide detailed knowledge of mechanism-of-action, efficacy and side-effect profile, and thus serve as an experimental basis to pave the way for future clinical evaluation.
Experiment size
The experimental setup includes a total of 3710 inbred mice, details of the various strains are further specified in the designated section of the application.
3R compliance
Group sizes are kept at a minimum required for statistically firm conclusions. Use of bioluminescence and extensive ex vivo studies yields a lot of information from each experiment and greatly limits the number of animals needed.